Clinical trials
Hepatitis clinical trials
Below are recruiting hepatitis clinical trials, each written for real people, not researchers. We’re tracking 484 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06947356Recruiting
TAF vs TDF to prevent passing hepatitis B to babies
This trial tests if TAF is safer and as effective as TDF for pregnant women with high hepatitis B viral loads to prevent passing the virus to their babies. You may qualify if you are pregnant, between 20-28 weeks, and have high viral levels.
Guangzhou, GuangdongAges 20–40 - NCT06950814Recruiting
Impact of extra treatment after surgery for liver cancer
This study looks at whether additional treatment after liver surgery (like chemotherapy or radiation) can help people with a rare and aggressive liver cancer called primary hepatic sarcomatoid carcinoma (PHSC). It only includes people who had surgery and no other cancer treatments before that.
Chengdu, SichuanAges 18 years+ - NCT06953479RecruitingPhase 4
Hepatitis C treatment for people awaiting trial in jail
This study offers a once-daily pill (Epclusa) to treat hepatitis C for people in jail who have never taken HCV medicine before. The goal is to see if starting treatment while incarcerated and continuing after release can cure the infection.
Cranston, Rhode IslandAges 18 years+ - NCT06966232RecruitingPhase 3
Using entecavir to prevent hepatitis B flare-up in gastrointestinal cancer patients
This trial tests whether giving the antiviral drug entecavir before or at the first sign of hepatitis B reactivation can prevent liver problems in gastrointestinal cancer patients who are inactive hepatitis B carriers and are starting chemotherapy or immunotherapy.
Guangzhou, GuangdongAges 18–75 - NCT06996938Recruiting
Sexual health screening for women in vulnerable situations
This study offers sexual health checkups and prevention services to women who are in difficult social or financial situations, including those without stable housing or who have sold sex for money. The goal is to see if these services are helpful and acceptable.
ParisAges 18 years+ - NCT07059403RecruitingPhase 1
Safety and dose study of a new hepatitis B vaccine in healthy adults
This study is testing a new hepatitis B vaccine called SN2001 in healthy adults. It will check how safe the vaccine is, what dose works best, and how well it helps your body build protection against hepatitis B.
Herston, QueenslandAges 18–55 - NCT07060547Recruiting
Blood test for alcohol-related liver disease
This study tests a new blood test (HepQuant DuO) to see how well it measures liver function in people with alcohol-related liver disease. If you have liver damage from alcohol and either a recent serious liver flare-up or also a fatty liver condition (NASH), this study may help your doctors understand your liver better.
Redwood City, CaliforniaAges 18 years+ - NCT07073612Recruiting
Fontan stent study for liver stiffness and exercise
This study looks at whether placing a stent in the Fontan blood vessel can improve liver health and exercise ability in teenagers and young adults. If you are between 12 and 21 years old and need a stent in your Fontan pathway, you may be able to join.
Los Angeles, CaliforniaAges 12–21 - NCT07122219Recruiting
Needle exchange access in federal prisons
This study looks at whether making needle and syringe programs easier to use helps more people in prison get clean needles. It's about reducing infection risks for everyone at the participating prisons.
Edmonton, AlbertaAges 18 years+ - NCT07137247Recruiting
How the immune system changes over time in chronic hepatitis B
This study tracks how the immune system works in people with chronic hepatitis B who haven't taken antiviral medication in the last 6 months. It aims to understand the natural history of the infection without treatment.
Guangzhou, GuangdongAges 1–80 - NCT07145801RecruitingPhase 2
Y-90 treatment response for liver cancer
This trial tests how well a Y-90 radiation treatment works for liver cancer that hasn't been treated before. It uses ultrasound imaging to check the response.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07152288RecruitingPhase 1
Study of HSK39297 in people with liver problems
This trial tests how a new drug, HSK39297, works in people with mild to moderate liver impairment (Child-Pugh A or B). It compares them to healthy volunteers to see how the liver affects the drug's safety and how the body processes it.
BeijingAges 18–70 - NCT07165002RecruitingPhase 1
Study of LY3537031 in people with and without liver problems
This trial tests how a new medicine, LY3537031, moves through the body and how safe it is for people with different levels of liver function. It includes people with normal livers and those with mild, moderate, or severe liver impairment.
KistarcsaAges 18–85 - NCT07178093Recruiting
Mushroom extract for liver cancer after TACE
This trial is testing if an extract from a medicinal mushroom (Antrodia cinnamomea) can help people with liver cancer who have had a treatment called TACE (chemoembolization). It looks at whether the mushroom extract can improve liver health and recovery after the procedure.
Taichung, TaiwanAges 20–80 - NCT07189377RecruitingPhase 4
Light, ex-vivo treatment and antivirals for lungs from hepatitis B donors
This trial tests a new way to safely use donor lungs that carry the hepatitis B virus (HBV). It combines a special light treatment, ex-vivo lung perfusion (cleaning the lungs outside the body), and antiviral medicines to prevent infection in the recipient. If you are on the lung transplant list and have been vaccinated against hepatitis B, this study may help expand your donor options.
Toronto, OntarioAges 18 years+ - NCT07192159Recruiting
Ultrasound vs MRI for measuring liver fat in MASLD
This study compares ultrasound (DeepUSFF) and MRI (MRI-PDFF) for measuring liver fat in people with MASLD (a type of fatty liver disease not caused by alcohol). It aims to see if ultrasound can be used as a cheaper, more accessible alternative to MRI.
Boardman, OhioAges 18 years+ - NCT07200193RecruitingPhase 1/Phase 2
Study of CRMA-1001 for chronic hepatitis B
This trial tests a new drug called CRMA-1001 in people with chronic hepatitis B who are already on antiviral therapy. The goal is to see if it can help control the virus better.
LyonAges 18–64 - NCT07202910Recruiting
Validating liver imaging in children
This study tests if non-invasive imaging (like ultrasound) can replace liver biopsies in children with liver disease. It may help avoid the need for a needle biopsy in the future.
Gothenburg, Västra Götaland CountyAges Up to 25 years - NCT06843148Recruiting
Does niacin help move fat from liver to fat tissue?
This study tests if niacin (a B vitamin) can help the body store fat safely in fat tissue instead of letting it build up in the liver. It may be an option for people with fatty liver linked to belly fat, without serious liver damage or other health issues.
Sherbrooke, QuebecAges 20–80 - NCT07257562Recruiting
Testing gut bacteria and amino acids to clear hepatitis B surface marker
This study tests whether a combination of a harmless gut bacterium (Bacteroides fragilis) and branched-chain amino acids (BCAAs, which are building blocks of protein) can help your body clear the hepatitis B surface antigen (HBsAg) from your blood. This may mean moving closer to a functional cure for chronic hepatitis B.
Fuzhou, FujianAges 18 years+ - NCT07270601Recruiting
Ultrasound test for liver fat
This study is testing a new ultrasound method to measure fat in the liver. It is for people who may have a liver condition or have risk factors like diabetes or obesity, as well as healthy volunteers.
Seattle, WashingtonAges 18–75 - NCT07275918RecruitingPhase 1
Study of SA1211 injection for chronic hepatitis B
This study tests a new injection called SA1211 for people with chronic hepatitis B. It will help see if the treatment is safe and how it works in the body.
Changchun, JilinAges 18–65 - NCT07276386RecruitingPhase 2
Combination therapy for metastatic uveal melanoma
This trial tests a two-part treatment for uveal melanoma that has spread to the liver. First, you get a liver-directed chemotherapy (melphalan) through a special procedure called PHP, then you receive an immunotherapy drug (tebentafusp) that helps your immune system attack the cancer.
Tampa, FloridaAges 18 years+ - NCT07326865Recruiting
Sugar metabolism study in obese patients with and without MASLD
This study looks at how the liver responds to sugar given through a vein in obese patients with and without a fatty liver condition called MASLD. It may help doctors understand why some people develop liver problems from sugar and fat.
Amsterdam, North HollandAges 35–65
Hear when a new Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis?
- Yes. Clin2 currently lists 484 recruiting hepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.